Home | My Account | Online Store | Contact & Demand | Press Room | About Us | FAQs
Home
Buy & Subscribe
Special Features
Products & Services
Online Store
Products by category
Products by publisher
Product lines
News Channels
Biotechnology
Therapeutic Areas
Business
RSS Feeds
Free RSS News
Get the latest news direct
to your desktop
feed image

Search in our News Channels

  

Search in our Online Store
Proteins & Peptides
Filter     Order     Display # 
Date Item Title Hits
01 Sep 2010 Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial 24
01 Sep 2010 Otoprotective effect of AM-111 also shown in model of cochlear ischemia 21
01 Sep 2010 Biodel Announces Name Change for Lead Product Candidate 19
31 Aug 2010 Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients 37
31 Aug 2010 Halozyme Provides HYLENEX(R) Product Reintroduction Update 49
26 Aug 2010 Swedish Orphan Biovitrum's Kineret(R) has Received Orphan Drug Designation in the USA 48
26 Aug 2010 Cypress Bioscience Acquires Novel Intranasal Carbetocin Therapy for Autism 52
26 Aug 2010 FibroGen Announces Results of 2-Year Study Demonstrating that Biosynthetic Corneas Formulated with Recombinant Human Type III Collagen Restore Vision and Promote Nerve Regeneration 43
26 Aug 2010 Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease 60
26 Aug 2010 Uniplas Clinical Development Successfully Completed 39
25 Aug 2010 ZymoGenetics Announces Completion of Enrollment in Phase 2b Clinical Trial with PEG-Interferon lambda in Hepatitis C 64
25 Aug 2010 Pharming Plans Submission Rhucin BLA To Us FDA End 2010 64
24 Aug 2010 Roche and Aileron Enter Multi-target Alliance to Develop Stapled Peptide Drugs for Diseases across Multiple Therapeutic Areas 78
24 Aug 2010 Kamada and Baxter Enter into a Strategic Agreement for the Distribution and Manufacture of Intravenous Liquid AAT to Treat Alpha-1 Antitrypsin Deficiency in the US 61
24 Aug 2010 PROLOR Biotech Receives FDA Clearance for a Phase II Trial of Its Long-Acting Human Growth Hormone in the U.S. 71
20 Aug 2010 Protalex, Inc. Announces Dosing of First Patient in a Phase 1b Study of PRTX-100 in Patients With Active Rheumatoid Arthritis 60
20 Aug 2010 Anchor Therapeutics Secures $10 Million Series B Financing to Advance Pepducin Drug Candidates 10
19 Aug 2010 Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain 131
18 Aug 2010 Palatin Technologies (PTN) Announces Positive Safety Results in Subcutaneous Bremelanotide Trial in Men 103
18 Aug 2010 BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. 54
18 Aug 2010 Bolder BioTechnology Announces $600,000 Grant from NIH to Study Long-Acting IL-11 Analog in Treating Acute Radiation Syndrome 80
18 Aug 2010 Immunomedics and GE Healthcare in Research Collaboration 56
17 Aug 2010 BAC and Octapharma Extend Collaboration for G-CSF Custom Ligand for Commercial Scale Manufacture 60
12 Aug 2010 BioMimetic Therapeutics Receives Orphan Drug Designation for rhPDGF-BB Treatment of Osteochondritis Dissecans 74
11 Aug 2010 Trigemina, Inc. Reports Positive Results with its Lead Compound TI-001 in a Phase IIa Clinical Trial for Chronic Daily Headache 76
10 Aug 2010 Vyteris Announces Positive Results From Phase II Clinical Trial of Transdermal Patch for Female Infertility 93
10 Aug 2010 Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL Ointment on Healing of Diabetic Foot Ulcers 57
10 Aug 2010 FDA Approves 8 mg Vial of NovoSeven RT for the Treatment of Hemophilia A or B with Inhibitors and Enhanced Shelf Life for All Vial Sizes 101
09 Aug 2010 Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A 91
09 Aug 2010 Dr Reddy’s launches darbepoetin alfa in India under the brand name ‘Cresp’ 106
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>
Results 1 - 30 of 2260

PipelineReview.com is powered by La Merie Business Intelligence La Merie Business Intelligence

For immediate assistance, please call us during business hours: Mon-Fri 09:00am - 18:30pm; GMT+01

La Merie S.L | Passatge Jordi Ferran, 20 | E-08028 Barcelona | T +34 93 342 91 97 | F +34 93 342 91 98 | Email info@lamerie.com | Internet www.lamerie.com
All contents © by La Merie S. L

Competitor Analysis Series

Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease

Order Now

Recommended Report

R&D Drug Pipeline Database
Order Now

Subscribe La Merie Biologics